Sam Brusco, Associate Editor08.15.22
Boston Scientific has acquired Obsidio, a company that developed the Gel Embolic Material (GEM) for embolization of blood vessels in peripheral vasculature. Financial terms were not disclosed.
The GEM technology is a semi-solid, proprietary material package in ready-to-use form, reducing preparation time required. It’s delivered through a catheter and its gel-like composition allows controlled placement in patient anatomy.
Unlike solid and liquid embolics that can take time to form blood flow obstruction, GEM conforms to the targeted vasculature and immediately creates a barrier.
"The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients," Peter Pattison, president, interventional oncology and embolization, Peripheral Interventions, Boston Scientific told the press. "This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions."
Boston Scientific expects the transaction to be immaterial to GAAP and adjusted earnings per share in 2022.
The GEM technology is a semi-solid, proprietary material package in ready-to-use form, reducing preparation time required. It’s delivered through a catheter and its gel-like composition allows controlled placement in patient anatomy.
Unlike solid and liquid embolics that can take time to form blood flow obstruction, GEM conforms to the targeted vasculature and immediately creates a barrier.
"The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients," Peter Pattison, president, interventional oncology and embolization, Peripheral Interventions, Boston Scientific told the press. "This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions."
Boston Scientific expects the transaction to be immaterial to GAAP and adjusted earnings per share in 2022.